Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

Canadian manufacturer Balcan Plastics is looking to double its workforce at the facility. The premier business information ...

About 1 in 5 classified as overweight based on BMI alone considered to have obesity according to European society definition.

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,701.53 today based on a price of $771.99 for LLY at the time of writing.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?